Aimmune Therapeutics (AIMT) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from a buy rating to a hold rating in a research note published on Wednesday morning.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

A number of other research analysts have also weighed in on AIMT. Wedbush reissued an ourperform rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a report on Monday, August 14th. ValuEngine lowered shares of Aimmune Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. BidaskClub lowered shares of Aimmune Therapeutics from a hold rating to a sell rating in a report on Friday, August 11th. Piper Jaffray Companies raised their target price on shares of Aimmune Therapeutics from $38.00 to $60.00 and gave the company an overweight rating in a report on Tuesday, December 5th. Finally, Roth Capital assumed coverage on shares of Aimmune Therapeutics in a report on Monday, November 20th. They issued a buy rating and a $60.00 target price for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Aimmune Therapeutics currently has a consensus rating of Hold and an average price target of $53.80.

Shares of Aimmune Therapeutics (NASDAQ AIMT) opened at $34.16 on Wednesday. Aimmune Therapeutics has a fifty-two week low of $15.97 and a fifty-two week high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.09. equities analysts forecast that Aimmune Therapeutics will post -2.54 earnings per share for the current year.

In related news, insider Douglas T. Sheehy sold 1,906 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $38.66, for a total value of $73,685.96. Following the completion of the sale, the insider now directly owns 1,906 shares in the company, valued at $73,685.96. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Stephen George Dilly sold 100,000 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $25.01, for a total value of $2,501,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 274,986 shares of company stock valued at $7,533,100. 24.56% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. lifted its position in Aimmune Therapeutics by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 87,057 shares of the biotechnology company’s stock worth $1,892,000 after buying an additional 4,788 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Aimmune Therapeutics in the second quarter worth $442,000. Goldman Sachs Group Inc. lifted its position in Aimmune Therapeutics by 139.9% in the second quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock worth $4,675,000 after buying an additional 132,603 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Aimmune Therapeutics by 16.9% in the second quarter. Bank of New York Mellon Corp now owns 131,353 shares of the biotechnology company’s stock worth $2,700,000 after buying an additional 19,016 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in Aimmune Therapeutics in the second quarter worth $360,000. Institutional investors own 73.34% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Aimmune Therapeutics (AIMT) Rating Lowered to Hold at Zacks Investment Research” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://transcriptdaily.com/2017/12/10/aimmune-therapeutics-aimt-rating-lowered-to-hold-at-zacks-investment-research.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply